Tags

Type your tag names separated by a space and hit enter

Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
Ther Adv Cardiovasc Dis. 2011 Dec; 5(6):297-304.TA

Abstract

BACKGROUND

Controversy exists as to whether angiotensin (1-7) (Ang (1-7)) acts as a protective hormone against renal injury.

METHODS

We compared the degree of improvement of hypertensive nephropathy following 8 weeks' treatment with either the angiotensin II receptor type 1 antagonist olmesartan medoxomil or the cardioselective beta blocker atenolol in 8-week-old spontaneously hypertensive rats (SHRs).

RESULTS

Both treatment regimens reduced mean blood pressure in a similar fashion, while bradycardia was present only in atenolol-treated SHRs. The heart weight:body weight ratio fell more in SHRs medicated with olmesartan versus those receiving atenolol. These changes were associated with increases in plasma Ang II in SHRs given the angiotensin II receptor blocker. At the end of treatment, plasma Ang (1-7) was higher in the olmesartan than atenolol or vehicle groups. The glomerular sclerosis (GS) index was lowered by olmesartan and atenolol compared with the vehicle group. While both olmesartan and atenolol attenuated renal perivascular collagen deposition (PVCD), the greatest effect was observed in SHRs receiving olmesartan. Elevations in plasma Ang (1-7) correlated negatively with reductions in GS or PVCD index, respectively.

CONCLUSIONS

While control of blood pressure remains a critical factor in the prevention of hypertensive nephropathy, Ang (1-7) may play a substantial role in preventing the structural changes in glomerulus through its effect on regulations of blood pressure and renal function.

Authors+Show Affiliations

Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime 791-0295, Japan.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22089474

Citation

Igase, Michiya, et al. "Attenuation of Hypertension-mediated Glomerulosclerosis in Conjunction With Increased Angiotensin (1-7)." Therapeutic Advances in Cardiovascular Disease, vol. 5, no. 6, 2011, pp. 297-304.
Igase M, Yokoyama H, Ferrario CM. Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7). Ther Adv Cardiovasc Dis. 2011;5(6):297-304.
Igase, M., Yokoyama, H., & Ferrario, C. M. (2011). Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7). Therapeutic Advances in Cardiovascular Disease, 5(6), 297-304. https://doi.org/10.1177/1753944711429343
Igase M, Yokoyama H, Ferrario CM. Attenuation of Hypertension-mediated Glomerulosclerosis in Conjunction With Increased Angiotensin (1-7). Ther Adv Cardiovasc Dis. 2011;5(6):297-304. PubMed PMID: 22089474.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7). AU - Igase,Michiya, AU - Yokoyama,Hiroshi, AU - Ferrario,Carlos M, Y1 - 2011/11/16/ PY - 2011/11/18/entrez PY - 2011/11/18/pubmed PY - 2012/4/20/medline SP - 297 EP - 304 JF - Therapeutic advances in cardiovascular disease JO - Ther Adv Cardiovasc Dis VL - 5 IS - 6 N2 - BACKGROUND: Controversy exists as to whether angiotensin (1-7) (Ang (1-7)) acts as a protective hormone against renal injury. METHODS: We compared the degree of improvement of hypertensive nephropathy following 8 weeks' treatment with either the angiotensin II receptor type 1 antagonist olmesartan medoxomil or the cardioselective beta blocker atenolol in 8-week-old spontaneously hypertensive rats (SHRs). RESULTS: Both treatment regimens reduced mean blood pressure in a similar fashion, while bradycardia was present only in atenolol-treated SHRs. The heart weight:body weight ratio fell more in SHRs medicated with olmesartan versus those receiving atenolol. These changes were associated with increases in plasma Ang II in SHRs given the angiotensin II receptor blocker. At the end of treatment, plasma Ang (1-7) was higher in the olmesartan than atenolol or vehicle groups. The glomerular sclerosis (GS) index was lowered by olmesartan and atenolol compared with the vehicle group. While both olmesartan and atenolol attenuated renal perivascular collagen deposition (PVCD), the greatest effect was observed in SHRs receiving olmesartan. Elevations in plasma Ang (1-7) correlated negatively with reductions in GS or PVCD index, respectively. CONCLUSIONS: While control of blood pressure remains a critical factor in the prevention of hypertensive nephropathy, Ang (1-7) may play a substantial role in preventing the structural changes in glomerulus through its effect on regulations of blood pressure and renal function. SN - 1753-9455 UR - https://www.unboundmedicine.com/medline/citation/22089474/Attenuation_of_hypertension_mediated_glomerulosclerosis_in_conjunction_with_increased_angiotensin__1_7__ L2 - https://journals.sagepub.com/doi/10.1177/1753944711429343?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -